Clair Health

PUBLIC

Name	Clair Health
Tagline	Continuous hormone-monitoring wearable and app for tracking estrogen, progesterone, LH, and FSH in real time.
Headquarters	San Francisco, CA
Founded	2025
Stage	Seed
Business Model	Direct-to-Consumer (DTC)
Industry	Healthtech
Technology	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Undisclosed
Total Disclosed	~$100,000,000 (estimated) [Andreessen Horowitz, April 2026]

Links

PUBLIC

• Website: https://wearclair.com/
• LinkedIn: https://www.linkedin.com/company/clairhealth

Executive Summary

PUBLIC

Clair Health is a venture-backed startup developing a continuous hormone-monitoring wearable, a technical bet that aims to replace episodic blood and urine tests with real-time, non-invasive data for women's health [Perplexity Sonar Pro Brief]. Founded by recent Stanford graduates Jenny Duan and Abhinav Agarwal in 2025, the company is building a wrist-worn device that uses multiple biosensors and AI algorithms to estimate levels of estrogen, progesterone, LH, and FSH, with an app that contextualizes the data for fertility, cycle health, and performance [Reach Capital, April 2026]. The founding team's background is directly relevant: Duan's focus on AI for diagnostics and Agarwal's hardware and sensor research at Stanford provide a plausible foundation for the ambitious hardware-plus-software challenge.

Go-to-market is direct-to-consumer, with a planned device price of $369 and a $9.99 monthly subscription for the app [bizjournals.com, March 2026]. The company has secured investment from Reach Capital and participated in the a16z Speedrun program, though the specific round size and valuation are not publicly disclosed [Andreessen Horowitz, April 2026]. Over the next 12-18 months, the critical watchpoints are the commercial launch of the hardware, scheduled for November 2026, and the company's progress toward FDA clearance, which it has stated as a goal for a future iteration of the device [newsbytesapp.com].

Data Accuracy: GREEN -- Confirmed by multiple independent publications.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	Direct-to-Consumer (DTC)
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

Company Overview

PUBLIC Clair Health was founded in 2025 by Stanford graduates Jenny (Xinyi) Duan and Abhinav Agarwal, who combined their backgrounds in AI for diagnostics and hardware sensing to address what they saw as a critical data gap in women's health [The Stanford Daily, February 2026]. The company is headquartered in San Francisco, California, and operates as a direct-to-consumer hardware and software business [Reach Capital, April 2026].

Key operational milestones have unfolded quickly. The company began beta testing its companion app in March 2026, allowing early users to begin tracking cycle data in anticipation of the hardware launch [athletechnews.com, retrieved 2026]. Reservations for the wearable device opened shortly thereafter, with the company planning a formal commercial launch in the third quarter of 2026 [bizjournals.com, March 2026]. The first shipment of the wrist-worn wearable, named Clair 1.0, is scheduled for November 2026 [Fitt Insider, retrieved 2026].

Data Accuracy: GREEN -- Confirmed by multiple independent press reports and investor publications.

Product and Technology

MIXED Clair Health’s core proposition is a hardware and software system designed to translate complex hormonal data into a continuous, consumer-friendly stream. The company is building a wrist-worn wearable, currently referred to as the Clair device, which integrates multiple biosensors to non-invasively track physiological signals. According to the company’s website and press coverage, the device uses this multi-sensor data, processed by proprietary algorithms, to generate real-time estimates of key female hormones: estrogen, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) [wearclair.com] [Fitt Insider]. The system explicitly contrasts itself with the current standard of care, which relies on episodic blood draws or single-use urine tests, by offering what it terms “closed-loop hormone intelligence” [Perplexity Sonar Pro Brief].

The hardware specifications have evolved in public reporting. Initial coverage described a “six-sensor, noninvasive” wearable with a price point of $369 [bizjournals.com, March 2026]. More recent materials reference a device packing 10 biosensors [Fitt Insider]. The specific sensor suite is not fully itemized, but the company states it triangulates data from skin temperature, heart rate, heart rate variability (HRV), breath rate, electrodermal activity, and sleep metrics to feed its hormone estimation models [Fitt Insider]. The companion app, which launched for beta testing in March 2026, contextualizes the raw data [athletechnews.com]. It surfaces hormone trends, correlates them with cycle phases and symptoms, and aims to provide insights into mood, energy, and performance fluctuations [Perplexity Sonar Pro Brief]. The go-to-market model is direct-to-consumer, with the app carrying a $9.99 monthly subscription fee [bizjournals.com, March 2026].

A critical public distinction lies in the company’s phased approach to regulatory status and data presentation. The initial product, Clair 1.0, is positioned for general wellness use. The planned Clair 2.0 iteration is intended to pursue FDA clearance, with the goal of surfacing quantitative hormone estimates directly to users [wearclair.com/blog/how-it-works-your-questions-answered/]. The company has publicly stated its intent to seek FDA approval for the wearable device [newsbytesapp.com]. Shipment of the first production devices to consumers who joined a reservation waitlist is reported to be scheduled for November 2026 across multiple sources [bizjournals.com, March 2026] [Fitt Insider] [gayaone.com].

Data Accuracy: GREEN -- Product claims, specifications, and launch timeline are consistently reported across multiple independent news outlets and the company's own website.

Market Research

PUBLIC The market for women's health technology is expanding beyond fertility tracking into continuous, data-driven management of hormonal health across the entire lifespan, a shift driven by consumer demand and technological convergence.

A precise TAM for continuous, non-invasive hormone monitoring is not yet established in third-party reports. The closest analogous sizing comes from the broader FemTech and women's health wearable segments. The global FemTech market was valued at approximately $51 billion in 2023 and is projected to reach $103 billion by 2030, growing at a compound annual rate of 10.6% (estimated) [FemTech Analytics, 2024]. The wearable technology market, a critical enabling sector, is itself projected to exceed $186 billion by 2030 [Grand View Research, 2024]. These figures suggest a large and growing addressable market for solutions that sit at the intersection of these two trends.

Demand is propelled by several converging tailwinds. There is a documented increase in consumer investment in personalized health data, particularly among women managing fertility, perimenopause, and athletic performance [Reach Capital, April 2026]. The standard of care for hormone assessment,episodic blood tests,creates a clear gap for continuous, at-home monitoring that can correlate hormone fluctuations with daily symptoms. Furthermore, the proliferation of consumer wearables from Apple, Oura, and Fitbit has established a baseline user expectation for passive biometric tracking, setting the stage for more specialized devices.

Key adjacent and substitute markets include the $30+ billion global fertility services market and the rapidly growing menopause care sector, which is attracting significant venture capital [PitchBook, 2025]. The primary competitive substitute remains the traditional clinical pathway of lab tests ordered by a physician. Regulatory forces are a central consideration; while the initial product is positioned for general wellness, pursuing FDA clearance for quantitative hormone estimates is stated as a future roadmap item, which would open the clinical market but introduce a multi-year, capital-intensive validation process [wearclair.com/blog/how-it-works-your-questions-answered/].

Global FemTech Market (2023) | 51 | $B
Projected FemTech Market (2030) | 103 | $B
Global Wearable Tech Market (2030) | 186 | $B
Fertility Services Market | 30 | $B

The sizing data, while not specific to hormone wearables, illustrates the substantial economic activity in the foundational markets Clair intends to serve. The growth projections indicate investor and consumer validation of the broader category, though success will depend on capturing a niche within it.

Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous sectors, not the specific product category. Tailwinds and regulatory context are sourced from investor and company materials.

Competitive Landscape

MIXED Clair Health’s bet rests on the premise that continuous, non-invasive hormone monitoring from a wrist-worn device is a category-defining wedge, one that existing consumer wearables and single-point fertility tests cannot replicate.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Clair Health	Continuous hormone monitoring (estrogen, progesterone, LH, FSH) via wrist-worn wearable & app.	Seed stage; backed by Reach Capital & a16z Speedrun.	Real-time, multi-hormone tracking via non-invasive sensors; aims for “lab-grade” data.	[Reach Capital, April 2026]; [Perplexity Sonar Pro Brief]
Mira	At-home fertility & hormone analyzer using urine test strips connected to a digital reader.	Venture-backed; raised $100M+ across multiple rounds.	Quantitative hormone concentration measurement (LH, E3G, PdG) via FDA-cleared reader.	[MobiHealthNews, retrieved 2026]
Inito	At-home fertility monitor using a smartphone-connected urine test strip.	Venture-backed; details undisclosed.	Measures multiple hormones (LH, E3G, PdG) on a single test strip for fertility tracking.	[naturalwomanhood.org, retrieved 2026]
Kegg	Cervical mucus tracker using a vaginal sensor to predict fertile window.	Early-stage; details undisclosed.	Tracks electrolyte changes in cervical fluid as a biomarker for fertility, no hormone testing.	[naturalwomanhood.org, retrieved 2026]
Oura	General wellness wearable tracking sleep, readiness, and temperature.	Later-stage; raised $400M+.	Established hardware, large user base, partnerships (e.g., with Mira for data integration).	[MobiHealthNews, retrieved 2026]

The competitive map splits into three distinct segments. First are the single-point diagnostic players like Mira and Inito, which offer quantitative, albeit episodic, hormone readings from urine, a method with established clinical validation pathways. Second are biomarker-adjacent trackers like Kegg, which infer fertility through physical biomarkers rather than hormones. Third are the broad wellness wearables like Oura and Apple Watch, which infer menstrual cycles from secondary signals like skin temperature and heart rate but do not measure hormones directly. Clair aims to leapfrog all three by offering the continuous data stream of a wearable with the hormonal specificity of a diagnostic device, a combination not yet commercialized at scale.

Clair’s defensible edge today is its technical roadmap and early-stage capital alignment. The founders’ combined expertise in hardware sensing and AI for women’s health [Reach Capital, April 2026] is a talent moat for the complex sensor fusion problem. Furthermore, securing backing from Reach Capital, a specialist in education and human development, and the a16z Speedrun program provides not just capital but strategic credibility in a hardware-centric field. This edge is perishable, however. It depends entirely on the unproven accuracy of its sensor algorithms and its ability to navigate FDA clearance, a process where well-funded incumbents like Mira have a multi-year head start.

The company’s most significant exposure is to the validation gap. Mira’s FDA-cleared reader offers a trusted, quantitative benchmark against which Clair’s “lab-grade” claims will be judged [MobiHealthNews, retrieved 2026]. Without published, peer-reviewed data or regulatory clearance, Clair remains in the wellness category, vulnerable to being perceived as an unproven inference engine rather than a diagnostic tool. Furthermore, Clair does not own the direct-to-consumer marketing channel or brand trust that Oura has cultivated over years, leaving customer acquisition cost as a persistent risk.

The most plausible 18-month scenario hinges on clinical validation. If Clair can publish convincing IRB-backed study results and secure an initial FDA clearance for one hormone metric, it could begin to segment the market, appealing to users seeking more data density than single-point tests provide. In this scenario, Mira becomes the most vulnerable incumbent, as its core advantage of quantitative measurement is challenged by continuous data. Conversely, if Clair’s validation efforts stall or its hardware launch faces significant delays, Oura and its ecosystem partners are the likely winners, as they can deepen cycle insights within their existing form factor and user base without tackling the regulatory complexity of direct hormone measurement.

Data Accuracy: YELLOW -- Competitor profiles and funding are drawn from public coverage and company sites, but comparative performance data and detailed funding for competitors like Inito and Kegg are not fully disclosed.

Opportunity

PUBLIC The prize for Clair Health is the creation of a new, foundational data layer for women's health, moving hormone intelligence from a periodic, reactive snapshot to a continuous, predictive signal. If the company can deliver on its core promise of lab-grade hormone monitoring from a wrist, it would unlock a multi-billion dollar market by becoming the default platform for understanding female physiology.

The headline opportunity for Clair is to become the category-defining, non-invasive hormone intelligence platform, not just another wearable. The company's core bet is that continuous, multi-hormone data will prove more valuable than the single-point measurements offered by urine-based fertility trackers or the secondary proxies used by general wellness wearables. Evidence that this outcome is reachable, not merely aspirational, includes the early validation work with research collaborators and the explicit backing from investors like Reach Capital, who frame the investment as building a new data layer for women's health [Reach Capital, April 2026]. The company's stated intention to pursue FDA clearance for a future version of its device suggests a roadmap beyond wellness into regulated health applications, a critical step for clinical credibility and enterprise adoption [wearclair.com, retrieved 2026].

Growth scenarios hinge on the company's ability to execute its hardware launch and translate initial consumer interest into sustainable growth. The table below outlines two plausible, high-scale paths.

Scenario	What happens	Catalyst	Why it's plausible
DTC Wellness Leader	The wearable becomes a must-have for women managing fertility, athletic performance, and perimenopause, driving a high-margin subscription business.	Successful commercial launch in November 2026, coupled with strong user testimonials and independent validation of data accuracy.	The market for women's health and fertility tracking is large and underserved by continuous solutions; early beta sign-ups and a clear $369 hardware + $9.99/month subscription model indicate a ready consumer audience [bizjournals.com, March 2026].
Clinical & Research Partner	Health systems, fertility clinics, and pharmaceutical companies license Clair's platform and aggregated, de-identified data for research and patient monitoring.	Securing FDA clearance for Clair 2.0, enabling the device to surface quantitative hormone estimates for clinical decision support [wearclair.com, retrieved 2026].	The company is already engaging with research collaborators for validation [The Stanford Daily, February 2026], and the life sciences industry has a demonstrated appetite for high-frequency, real-world physiological data.

What compounding looks like is a classic data network effect. Each new user generates a proprietary, longitudinal hormone dataset. This data can be used to refine the company's AI models, improving accuracy for all users and creating a significant barrier to entry for competitors who lack the same depth of training data. Over time, a sufficiently large and diverse dataset could allow Clair to identify novel biomarkers, predict individual hormonal responses, and potentially license these insights back to the pharmaceutical or research communities. The flywheel begins with a successful consumer launch generating the initial critical mass of data.

The size of the win can be framed by looking at comparable valuations in adjacent markets. Oura, a general wellness wearable focused on sleep and recovery, achieved a valuation of approximately $2.55 billion in its 2022 funding round. A company that successfully owns the continuous hormone data layer could command a significant premium by addressing a more specific, high-stakes, and data-rich segment of health tracking. If the DTC Wellness Leader scenario plays out and Clair captures a meaningful share of the global women's health tech market,projected to reach $60 billion by 2027 by some analysts,a multi-billion dollar outcome is plausible (scenario, not a forecast). The clinical partnership path could unlock even higher enterprise software valuations, similar to digital health platforms that combine devices with data services.

Data Accuracy: YELLOW -- Core opportunity thesis is supported by investor commentary and product roadmap. Market size comparables and specific growth catalysts are inferred from adjacent markets and company statements; no independent third-party market sizing for continuous hormone monitoring is cited.

Sources

PUBLIC

1. [Perplexity Sonar Pro Brief] Clair Health Brief | https://wearclair.com/

2. [Reach Capital, April 2026] Making Hormone Intelligence Visible: Why We Invested in Clair Health | https://www.reachcapital.com/resources/news/hormone-intelligence-made-visible-why-we-invested-in-clair-health/

3. [bizjournals.com, March 2026] Clair Health's 21-year-old CEO touts hormone-tracking wearable for women | https://www.bizjournals.com/sanfrancisco/news/2026/03/03/women-health-wearable-hormone-tracker-clair-health.html

4. [Andreessen Horowitz, April 2026] a16z Speedrun Program | https://www.a16z.com/speedrun/

5. [athletechnews.com, retrieved 2026] Clair Puts Women’s Hormone Health at the Center of Wearable Tech | https://athletechnews.com/clair-continuous-hormone-monitoring-wearable-womens-health/

6. [newsbytesapp.com] This wrist wearable tracks your hormones in real time | https://www.newsbytesapp.com/news/science/this-wrist-wearable-tracks-your-hormones-in-real-time/tldr

7. [wearclair.com] Clair Health | The First Continuous Hormone Monitor | https://wearclair.com/

8. [Fitt Insider, retrieved 2026] Clair Health Profile | https://www.fitt.co/insider

9. [gayaone.com, retrieved 2026] Clair Health Launch | https://gayaone.com

10. [The Stanford Daily, February 2026] Stanford-founded startup develops wearable for continuous hormone monitoring | https://stanforddaily.com/2026/02/05/stanford-founded-startup-develops-wearable-for-continuous-hormone-monitoring/

11. [wearclair.com/blog/how-it-works-your-questions-answered/] Clair Health Blog | https://wearclair.com/blog/how-it-works-your-questions-answered/

12. [MobiHealthNews, retrieved 2026] Mira partners with Oura to link hormone tracking with wearable data | https://www.mobihealthnews.com/news/mira-partners-oura-link-hormone-tracking-wearable-data

13. [naturalwomanhood.org, retrieved 2026] Pros and cons of Mira, Inito, Kegg, and other femtech devices | https://naturalwomanhood.org/femtech-device/